CHAIR: Jeffrey Weitzel, MD, City of Hope National Medical Center, Duarte, CA, USA
CHAIR: Ephrat Levy-Lahad, MD, Shaare Zedek Medical Center, Jerusalem, Israel
CHAIR: Antonis Antoniou PhD, University of Cambridge, Cambridge, UK
Moderated one-hour interactive discussions with the aim of fostering bilateral knowledge transfer. Participants will rank these SIGs in order of preference and will be assigned to participate in two SIGs on a first-come, first-reserved basis.
In this session, attendees will join the presenters in exploring clinico-pathological aspects of a set of well-known and less well-known breast and ovarian cancer susceptibility genes. Dr. Tischkowitz will focus on CDH1, Dr. Hoogerbrugge on PTEN and NTHL1 and Dr. Weitzel will discuss TP53. Attendees will be encouraged to send in specific cases in advance for discussion at the SIG.
In this interactive case-based session, Dr. Hurley will explore advance concepts in genetic counselling and will show how counsellors can help clients cope with the challenges associated with discovering their genetic status.
In this session, the three presenters will discuss the latest research on prevention, early diagnosis and treatment of three cancers that are associated with germline mutations in HRD genes. Attendees will be encouraged to send in questions relating to these topics in advance for discussion at the SIG.
In this session, the four experts will discuss the role of clinical testing for moderate risk breast and ovarian cancer susceptibility genes. They will review data on the cancer risks associated with pathogenic variants in each of the major moderate risk genes (e.g. ATM, BARD1, BRIP1, CHEK2, RAD51C, RAD51D) and will discuss emerging candidate genes. Models to assess risk will be discussed, as will counseling challenges. The pathology of tumors associated with pathogenic variants in these genes will be considered.
Some of the issues that will be discussed in this interactive session include genetic counselling in the private direct to consumer testing era, patenting of genes and its influence on data sharing, secrecy vs open innovation, ethical aspects of large-scale genomic sequencing and genetic discrimination. Attendees will be encouraged to send in specific ethics questions in advance for discussion at the SIG.
Ovarian cancer is one of the most preventable cancers. In this unique session, five leading experts will discuss the epidemiology of, and inherited contribution to, ovarian cancer, the role of risk assessment in management, the molecular genetics and pathology of the main subtypes of ovarian cancer, and where new treatments are taking the field.